Fluocinolone participated in clinical trials for the treatment of Oral Lichen Planus and Candida Infection.

Clomegestone (clomagestone) is an investigational steroidal progestogen. Clomegestone exhibits anti-estrogenic activity in estrone stimulated immature mice when administered orally at 100 ug.

Cimoxatone is a fully reversible inhibitor selective for the A form of monoamine oxidase. Oral administration of Cimoxatone increased brain noradrenaline, dopamine, and serotonin and decreased DOPAC , 5-HIAA, and 3-methoxy-4-hydroxyphenylethylene glycol sulfate.

Betamicin is an aminoglycoside antibiotic

Cefaparole (cephaparole) is a cephem antibiotic of the cephalosporin subclass that was never marketed and used as phmarceutical intermediates for other drugs.

FLUMINOREX is an anorexic agent.

Colestolone (5 alpha-cholest-8(14)-en-3 beta-ol-15-one) is an inhibitor of sterol biosynthesis. The compound reduces the level of 3-hydroxy-3-methylglutaryl coenzyme A reductive activity in cultured mammalian cells. In nonhuman primates, the compound decreases the levels of total serum cholesterol and low-density lipoprotein and increases the percentage of total cholesterol associated with high-density lipoprotein.

Pentamorphone was developed as a highly potent opioid with rapid onset and short duration of action that has been reported to produce analgesia with limited depression of ventilation. Pentamorphone participated in a clinical trial for the management of postoperative pain. However, no acute cardiorespiratory changes were observed. The drug was ineffective for treating acute postoperative pain after major surgery. In addition, was shown that pentamorphone, 10 micrograms/kg, does not seem to offer any significant advantage over opioids currently used for anesthesia in patients undergoing elective coronary artery bypass grafting (CABG). That is why its further development was discontinued.

16,16-dimethyl Prostaglandin E2 acts as an agonist on most prostaglandin E (EP) receptor subtypes, it has prolonged half-life in vivo, because it is not a substrate for the enzyme 15-hydroxy prostaglandin dehydrogenase. This compound was studied by Fate Therapeutics in phase I clinical trials under the name FT1050 or ProHema-CB for pediatric patients with hematologic malignancies. However, this study was terminated.

Androsterone, a neurosteroid, acts as a positive allosteric modulator of GABA(A) receptors, that can cross into the brain and could have effects on brain function. It was discovered, that the association of beta subunits with alpha subunits GABA(A) receptor affects the sensitivity of glycine receptors to androsterone. In spite of that, androsteron is considered as an inactive metabolite of testosterone. In addition, was studied that androsterone possessed anticonvulsant properties. Although of low potency, the androsterone was present in high abundance and was able to represent endogenous modulator of seizure susceptibility.